Movement Alert｜Twist Bioscience Rises 5.51% in Regular Trading, Buoyed by Canaccord Genuity Buy Rating with $90 Target Price

Market Focus06-16

On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.

On the news front, Canaccord Genuity initiated coverage with a Buy rating and a $90 price target, well above the analyst consensus target of $73.12 per FactSet data. The $90 target implies approximately 5.6% upside from current levels and has provided a clear near-term catalyst for the stock. The upgraded target marks a notable premium to Wall Street consensus, signaling bullish conviction in the company's growth trajectory.

Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, serving healthcare, food and agriculture, industrial chemicals, and data storage markets. The stock has gained significant ground from its 52-week low of $23.30, with shares now trading near recent highs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114521854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114521854","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Rises 5.51% in Regular Trading, Buoyed by Canaccord Genuity Buy Rating with $90 Target Price","media":"Market Focus","content":"<p><p>On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.</p><p>On the news front, Canaccord Genuity initiated coverage with a Buy rating and a $90 price target, well above the analyst consensus target of $73.12 per FactSet data. The $90 target implies approximately 5.6% upside from current levels and has provided a clear near-term catalyst for the stock. The upgraded target marks a notable premium to Wall Street consensus, signaling bullish conviction in the company's growth trajectory.</p><p>Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, serving healthcare, food and agriculture, industrial chemicals, and data storage markets. The stock has gained significant ground from its 52-week low of $23.30, with shares now trading near recent highs.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Rises 5.51% in Regular Trading, Buoyed by Canaccord Genuity Buy Rating with $90 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Rises 5.51% in Regular Trading, Buoyed by Canaccord Genuity Buy Rating with $90 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-16 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.</p><p>On the news front, Canaccord Genuity initiated coverage with a Buy rating and a $90 price target, well above the analyst consensus target of $73.12 per FactSet data. The $90 target implies approximately 5.6% upside from current levels and has provided a clear near-term catalyst for the stock. The upgraded target marks a notable premium to Wall Street consensus, signaling bullish conviction in the company's growth trajectory.</p><p>Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, serving healthcare, food and agriculture, industrial chemicals, and data storage markets. The stock has gained significant ground from its 52-week low of $23.30, with shares now trading near recent highs.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1114521854","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114521854","pubTimestamp":1781618749,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.On the news front, Canaccord...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"动向提示|Twist Bioscience常规交易上涨5.51%，受Canaccord Genuity买入评级提振，目标价90美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.On the news front, Canaccord Genuity initiated coverage with a Buy rating and a $90 price target, well above the analyst consensus target of $73.12 per FactSet data. The $90 target implies approximately 5.6% upside from current levels and has provided a clear near-term catalyst for the stock. The upgraded target marks a notable premium to Wall Street consensus, signaling bullish conviction in the company's growth trajectory.Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, serving healthcare, food and agriculture, industrial chemicals, and data storage markets. The stock has gained significant ground from its 52-week low of $23.30, with shares now trading near recent highs.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114521854","isCrawlerRequest":true}